<DOC>
	<DOC>NCT01823315</DOC>
	<brief_summary>The investigators will conduct a trial to determine whether methotrexate single-dose treatment and methotrexate/Actinomycin-D single-dose treatment work well as multiple courses of single agent chemotherapy in low-risk gestational trophoblastic neoplasia.</brief_summary>
	<brief_title>Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>Patients who FIGO Stage I, II, or III criteria for lowrisk gestational trophoblastic neoplasia (GTN); WHO risk score 06; Age≤60 years; female, Chinese women; Initial treatment is chemotherapy; patients who received prior lowdose methotrexate for treatment of an ectopic pregnancy will be eligible for this study; Performance status: Karnofsky score≥60; Laboratory tests: WBC≥3.5×10(9)/L, ANC≥1.5×10(9)/L, PLT≥80×10(9)/L, serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal, BUN, Cr≤ normal Provide written informed consent. Patients with unconfirmed diagnosis of GTN; Patients with placentalsite trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT) WHO risk score &gt;6; With severe or uncontrolled internal disease, unable to receive chemotherapy; Concurrently participating in other clinical trials Unable or unwilling to sign informed consents; Unable or unwilling to abide by protocol.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>